{"id":"W2605189400","doi":"10.1200/jco.2012.30.15_suppl.tps2614","title":"A phase I study of BMS-936558 plus sunitinib or pazopanib in patients with metastatic renal cell carcinoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pazopanib; Sunitinib; Temsirolimus; Renal cell carcinoma; Tolerability; Internal medicine; Oncology; Everolimus; Bevacizumab; Pharmacology; Urology; Adverse effect; Chemotherapy; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors; Apoptosis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001721415,0.00252936,0.00345366,0.0007537834,0.0005859196,0.0012446,0.001466236,0.001357244,0.005572142],"category_scores_gemma":[0.0009338666,0.001055386,0.002009736,0.0007584676,0.001342645,0.001231087,0.0005313362,0.003633699,0.001673651],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001437946,"about_ca_system_score_gemma":0.002692399,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002116428,"about_ca_topic_score_gemma":0.004301162,"domain_scores_codex":[0.9993688,0.000246855,0.0000360442,0.0001286272,0.0000683837,0.0001511682],"domain_scores_gemma":[0.9990867,0.00009569275,0.0001454357,0.00007239971,0.00005387293,0.0005459571],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7193404,0.1288893,0.006792049,0.001423684,0.001892381,0.0005182698,0.0003972098,0.003900749,0.04938626,0.0003117653,0.00388548,0.08326252],"study_design_scores_gemma":[0.5661948,0.4215941,0.006782745,0.0000217586,0.0003810603,0.0002884509,0.00005408709,0.0007435185,0.002258931,0.0001162862,0.00153711,0.00002722779],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889498,0.001914914,0.0005398387,0.0004941884,0.0002004902,0.004531967,0.001280988,0.0001437225,0.001944015],"genre_scores_gemma":[0.9856988,0.002103031,0.002033059,0.0008296754,0.0002447312,0.003997645,0.002346357,0.00004129592,0.002705411],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005572142,"threshold_uncertainty_score":0.01864064,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1887988785238983,"score_gpt":0.4590881894758819,"score_spread":0.2702893109519836,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}